regulatory agencies including the European Medicines Agency and Health Canada have recommended that fluvoxamine's product labeling warn of this risk.

Fluvoxamine appears to be more tolerable than other SSRIs, particularly with respect to cardiovascular complications.

Medical uses

In many countries